Champions Oncology CSBR
NASDAQ CSBR
$4.79 -0.11 (-2.24%)
As of: Oct 14, 2026 · 1:42 PM EDT

Champions Oncology (CSBR) Gains from Sales and Divestitures (2021 - 2026)

Updated

Champions Oncology's Gains from Sales and Divestitures was -$1,000 in fiscal Q4 2026 (quarter ended Apr 30, 2026), compared with -$293,000 a year earlier.

Analysis

Champions Oncology (CSBR) Gains from Sales and Divestitures (2021 - 2026) Analysis & Trends

For FY2026 (ended Apr 30, 2026), Gains from Sales and Divestitures at Champions Oncology came in at -$111,000.

  • In earlier fiscal years, Gains from Sales and Divestitures was -$293,000 in FY2025, -$435,000 in FY2024 and $4,000 in FY2022.
  • The fiscal Q4 2026 figure marks the highest quarterly Gains from Sales and Divestitures since fiscal Q1 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Iqvia Holdings 43.59 Bn 35.30 Bn 1.44 Bn
2 Medpace Holdings 17.35 Bn 15.41 Bn 201.64 Mn
3 Charles River Laboratories International 14.57 Bn 13.77 Bn 363.37 Mn
4 Icon 13.15 Bn 10.26 Bn 479.29 Mn
5 Fortrea Holdings 2.02 Bn 1.40 Bn 139.20 Mn
6 Ginkgo Bioworks Holdings 720.92 Mn -41.17 Mn 18.44 Mn
7 Evotec SE 502.55 Mn -1.11 Bn -
8 Champions Oncology 66.57 Mn 41.65 Mn 7.70 Mn
9 MindWalk Holdings 63.08 Mn 26.73 Mn 1.61 Mn
10 Natural Alternatives International 6.81 Mn -21.27 Mn 1.73 Mn
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2026 -1,000.00
Jan 31, 2026 -89,000.00
Jul 31, 2025 -20,000.00
Apr 30, 2025 -293,000.00
Apr 30, 2024 -354,000.00
Jan 31, 2024 -16,000.00
Jul 31, 2021 4,000.00
API Access

Champions Oncology Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CSBR&period=max&api_key=YOUR_API_KEY